On March 10, 2026, Sunshine SwissCo, a consortium led by EQT, the Abu Dhabi Investment Authority (ADIA), and Auba Investment, officialised the launch of an accelerated bookbuilding process to professional investors in Switzerland and to qualified investors
Homburger advised 21Shares on the completion of a merger by absorption, pursuant to which FalconX, acquired 21Shares’ ultimate parent company. The transaction was completed in November 2025. Following the merger, 21Shares continues to operate as an
L’Oréal acquired an additional 10% stake in Galderma. In connection with the transaction, Bär & Karrer advised the buyer, Niederer Kraft Frey (NKF) supported Galderma, while Homburger represented EQT, leader in a consortiun
EQT, as part of a consortium of sellers, completed the sale of 8.4 % of Galderma’s share capital via an accelerated bookbuilding process. The consortium in question further includes Sunshine SwissCo, the Abu Dhabi Investment Authority (
Homburger advised EQT as part of a consortium of sellers, in connection with the sale of 7.1% of Galderma’s share capital via an accelerated bookbuilding process. The consortium in question further includes Sunshine SwissCo, the
Homburger acted as legal advisor to IonQ in its acquisition of a controlling stake in Geneva-based ID Quantique from South Korea’s SK Telecom. IonQ, a leading company in commercial quantum computing and networking, announced
Galderma Group AG , the pure-play dermatology category leader, has announced the launch of its Initial Public Offering on the SIX Swiss Exchange. According to various market sources and reports, the Skincare business is looking to
Homburger has appointed three new partners as of 1 January 2024 who will reinforce its teams of corporate and M&A. Anna Peter (pictured centre), Margrit Marti (pictured right) and Miguel Sogo (pictured left) are based
Homburger advised Tolremo therapeutics on the extension of its Series A financing round, bringing the total amount raised to USD 39 million (CHF 34.1 million). BioMedPartners led the round with participation from a new investor, Pierre Fabre
VectivBio Holding, a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare gastrointestinal conditions, and Ironwood Pharmaceuticals, a GI-focused healthcare company, announced that they had entered into an agreement for Ironwood to launch an
